An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma

Pancreas

Volumn 41, Issue 7, 2012, Pages 1001-1007

  Dima, Simona O ^a   Tanase, Cristiana ^b   Albulescu, Radu ^b   Herlea, Vlad ^a   Chivu Economescu, Mihaela ^c   Purnichescu Purtan, Raluca ^d   Dumitrascu, Traian ^a   Duda, Dan G ^e   Popescu, Irinel ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Department of Biochemistry and Proteomics   (United Kingdom)

^c STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

^d UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

angiogenic factors; inflammatory cytokines; pancreatic ductal adenocarcinoma; prognostic biomarkers

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; INFLAMMATORY CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE METASTASIS; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865861118     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182546e13     Document Type: Article

References (60)

1. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
2. Kawakami K, Kawakami M, Husain SR, et al. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002;62(13):3575-3580.
3. Lilemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin. 2000;50(4):241-268.
4. Okada S, Yoshimori M, Kakizoe T. Pancreatic cancer: medical aspects. Pancreas. 1998;16(3):349-354.
5. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15-36.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
8. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109-119.
9. Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292-301.
10. Emmrich J, Weber I, Nausch M, et al. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma. Digestion. 1998;59(3):192-198.
11. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149(2):319-328.
12. Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(4):726-731.
13. Goecke H, Forssmann U, Uguccioni M, et al. Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. Surgery. 2000;128(5):806-814.
14. Ryu B, Jones J, Hollingsworth MA, et al. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res. 2001;61(5):1833-1838.
15. Gumbs AA. Obesity, pancreatitis, and pancreatic cancer. Obes Surg. 2008;18(9):1183-1187.
16. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005;15(1):72-77.
17. Badea L, Herlea V, Dima SO, et al. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016-2027.
18. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29(3):179-187.
19. Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44(4):534-541.
20. Mews P, Phillips P, Fahmy R, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut. 2002;50(4):535-541.
21. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612-1616.
22. Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell. 2011;19(1):1-2.
23. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
24. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427.
25. Duda DG, Batchelor TT, Willett CG, et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007;13(6):223-230.
26. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327-338.
27. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev. 2007;33(3):230-283.
28. American Joint Committee on Cancer. Pancreatic cancer staging. In: American Joint Committee on Cancer, ed. Cancer Staging Manual. 6th ed. New York, NY:Springer; 2002.
29. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. J Comput Stat Data Anal. 1999;30:253-270.
30. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
31. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897-909.
32. Pistol-Tanase C, Raducan E, Dima SO, et al. Assessment of soluble angiogenic markers in pancreatic cancer. Biomark Med. 2008;2(5):447-455.
33. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-3622.
34. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210-221.
35. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15(3):167-170.
36. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(2):193-201.
37. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25(3):307-313.
38. Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101(12):2727-2736.
39. Wigmore SJ, Fearon KC, Sangster K, et al. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 2002;21(4):881-886.
40. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
41. Jiang SS, Fang WT, Hou YH, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010;16(17):4363-4373.
42. Li M, Zhang Y, Feurino LW, et al. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci. 2008;99(4):733-737.
43. Tang RF, Wang SX, Zhang FR, et al. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2005;4(3):460-463.
44. Martignoni ME, Kunze P, Hildebrandt W, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res. 2005;11(16):5802-5808.
45. Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319-4330.
46. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456-469.
47. Apte MV, Wilson JS. Stellate cell activation in alcoholic pancreatitis. Pancreas. 2003;27(4):316-320.
48. Fukuda A, Wang SC, Morris JP, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19(4):441-455.
49. Miyamoto M, Shimizu Y, Okada K, et al. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother. 1998;47(1):47-57.
50. Sclabas GM, Fujioka S, Schmidt C, et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005;11(2 Pt 1):440-449.
51. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12(4):375-391.
52. Ren Y, Poon RT, Tsui HT, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003;9(16 Pt 1):5996-6001.
53. Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005;11(11):1639-1643.
54. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;56(1):56-62.
55. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68(5):1443-1450.
56. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102- 106.
57. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001;21(2B):1355-1358.
58. Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol. 2005;32(11):2102-2108.
59. Hamacher R, Diersch S, Scheibel M, et al. Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer. Cytokine. 2009;46(2):182-186.
60. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25(3):387-408.